Comparing Protagonist Therapeutics (NASDAQ:PTGX) and TransCode Therapeutics (NASDAQ:RNAZ)

Protagonist Therapeutics (NASDAQ:PTGX) and TransCode Therapeutics (NASDAQ:RNAZ) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, earnings, dividends and profitability.

Analyst Ratings

This is a summary of current ratings and recommmendations for Protagonist Therapeutics and TransCode Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protagonist Therapeutics	0	2	15	1	2.94
TransCode Therapeutics	1	0	0	0	1.00

Protagonist Therapeutics presently has a consensus price target of $140.53, indicating a potential downside of 7.24%. Given Protagonist Therapeutics’ stronger consensus rating and higher possible upside, equities research analysts clearly believe Protagonist Therapeutics is more favorable than TransCode Therapeutics.

Profitability

This table compares Protagonist Therapeutics and TransCode Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Protagonist Therapeutics	29.40%	12.03%	11.23%
TransCode Therapeutics	N/A	-875.35%	-37.46%

Insider and Institutional Ownership

98.6% of Protagonist Therapeutics shares are owned by institutional investors. 5.2% of Protagonist Therapeutics shares are owned by insiders. Comparatively, 0.1% of TransCode Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Protagonist Therapeutics and TransCode Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protagonist Therapeutics	$281.99 million	34.76	-$130.15 million	$1.03	147.09
TransCode Therapeutics	N/A	N/A	-$34.66 million	($52.37)	-0.04

TransCode Therapeutics has lower revenue, but higher earnings than Protagonist Therapeutics. TransCode Therapeutics is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Protagonist Therapeutics has a beta of 1.78, suggesting that its stock price is 78% more volatile than the S&P 500. Comparatively, TransCode Therapeutics has a beta of 1.24, suggesting that its stock price is 24% more volatile than the S&P 500.

Summary

Protagonist Therapeutics beats TransCode Therapeutics on 13 of the 14 factors compared between the two stocks.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

About TransCode Therapeutics

TransCode Therapeutics, Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. In addition, the company developing TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. was incorporated in 2016 and is based in Boston, Massachusetts.